Clinical trials: Sexually Transmitted Diseases, Viral
HIV Infections
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
- Trial name
- NCT06741397
- Testing
- CAB LA, New formulation of CAB LA
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection, CMV Infection
Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals
The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral…
- Trial name
- NCT00168259
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- The Alfred
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus…
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- OPTIMA (NCT02258659)
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Chicago
HIV Infections
Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
The purpose of this study is to see whether or not an HIV vaccination will help the body control the amount of HIV virus in blood (viral load) in patients who are not taking anti-HIV medicines.
- Trial name
- NCT00021762
- Testing
- HIV-1 Immunogen, Structured Treatment Interruption
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Kidney Disease
A Study of Zidovudine in HIV-Infected Patients With Kidney Problems
To determine how zidovudine (AZT) for the treatment of HIV infection is metabolized and excreted or eliminated in patients with infected or diseased kidneys.
- Trial name
- NCT00000685
- Testing
- Zidovudine
- Where
- 2 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
The Use of Nutropin Depot in HIV-infected Adult Males
This is a pilot study. We will treat 10 HIV-infected adults (1/2 with lipoatrophy) with GH depot for one year. Results will be compared to data from 10 HIV patients (1/2 with lipoatrophy), treated with Nutropin AQ subcutaneously.
- Trial name
- NCT00286676
- Testing
- Nutropin, Oral Glucose Tolerance Test, Dual Energy X-ray Absorptiometry (DEXA)
- Where
- 3 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
HIV Infections
Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC
The study aims to ascertain whether the sole replacement of tenofovir with abacavir once a day improves the immunological response obtained with tenofovir + ddI or whether it is better to perform a double replacement of tenofovir…
- Trial name
- NCT00338390
- Testing
- Abacavir, Didanosine, Abacavir+Lamivudine
- Where
- 21 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Hospital de Granollers
HIV Infections
Immune Activation as a Cause of Insulin Resistance in Adults Living With HIV-1 on Effective Antiretroviral Therapy
The aim of this study is to characterize in non-viremic HIV-1 patients under antiretroviral therapy an immune activation profile that the investigators have previously shown to be strongly linked to hyperinsulinemia.
- Trial name
- MetACTIVIH (NCT04028882)
- Testing
- Signaling, metabolomic and transcriptomic analysis
- Where
- France
- Volunteers
- 148 people
- Sponsor
- University Hospital, Montpellier
Hiv, Contraception Behavior
TwySHE - An Mhealth Peer-navigator Intervention to Increase PrEP and Contraceptive Use
The goal of this clinical trial is to learn if the TwySHE intervention can increase the use of HIV prevention in at-risk female university students aged 18-24 in Zambia.
- Trial name
- NCT06852508
- Testing
- TwySHE
- Where
- Zambia
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HIV Infections, Acquired Immunodeficiency Syndrome
Longitudinal Study of Ocular Complications of AIDS (LSOCA)
To monitor trends over time, in the incidence of CMV retinitis and other ocular complications of AIDS To determine the effect of highly active anti-retroviral therapy (HAART)-induced immune status on the risk of developing CMV…
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- LSOCA (NCT00000168)
- Where
- 19 sites in United States
- Volunteers
- 2,392 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies.
- Trial name
- NCT00002210
- Testing
- Delavirdine mesylate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pharmacia and Upjohn
Human Immunodeficiency Virus
A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV
The CABOTEGRAVIR Long Acting + RILPIVIRENE Long Acting regimen was currently endorsed by guidelines worldwide as an option for the Treatment of HIV-1 Infection, however collecting real-world data closer to clinical practice use…
- Trial name
- CABO-CHANCE (NCT06518408)
- Testing
- Cabotegravir Injectable Product, Rilpivirine Injectable Product
- Where
- 15 sites in Spain
- Volunteers
- 287 people
- Sponsor
- University Hospital Virgen de las Nieves
HIV Infections
Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)
Long-term side effects of antiretrovirals (ART) have led to the introduction in clinical practice of NRTI-sparing regimens as double- or mono- therapy and their use is now recommended in specific populations by International…
- Trial name
- NCT04054089
- Testing
- Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy], dolutegravir 50 mg / lamivudine 300 mg
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Cristina Mussini
HIV Infections
Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)
This Cophar2 study is a trial which evaluates repeated early therapeutic drug monitoring, from weeks 2 to 24, after the initiation of HAART including either indinavir/r, lopinavir/r or the new 625 mg formulation of nelfinavir…
- Trial name
- NCT00122590
- Testing
- nelfinavir, lopinavir/r, indinavir
- Where
- France
- Volunteers
- 115 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
- Trial name
- HVTN 135 (NCT04607408)
- Testing
- CH505TF gp120, GLA-SE adjuvant
- Where
- South Africa
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infections
Assessing the Safety of Dapivirine Gel and Film Formulations
This is a study to determine the safety of dapivirine gel and dapvirine film for healthy, HIV-uninfected women aged 18-45 years using the product for 7 daily doses.
- Trial name
- NCT01548560
- Testing
- Dapivirine Vaginal Film, Dapivirine Vaginal Gel
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV, HIV Infections
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
The purpose of this study is to study how changes in the body during pregnancy influence the blood levels of TMC114 (darunavir) and ritonavir taken together, darunavir and cobicistat taken as a fixed-dose combination, TMC125…
- Conditions
- HIV, HIV Infections, Pregnancy
- Trial name
- NCT00855335
- Testing
- Darunavir, Ritonavir, Etravirine
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 77 people
- Sponsor
- Janssen Scientific Affairs, LLC
Infection, Human Immunodeficiency Virus
Evaluation of the Bioequivalence of a Combined Formulated Tablet
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01622790
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical benefit.
- Trial name
- NCT01776996
- Testing
- Continued Access Arm
- Where
- 28 sites in Argentina, Belgium and 5 more
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients
The purpose of this pilot study is to find out if taking hydroxychloroquine will decrease immune activation (stimulation of the body's defence system) in people with early HIV infection.
- Trial name
- HCQ-01 (NCT01067417)
- Testing
- Hydroxychloroquine
- Volunteers
- 83 people
- Sponsor
- Medical Research Council
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.